Loading
Neurocrine Biosciences Inc Stock: price and insider trades · United States
Neurocrine Biosciences Inc: what insiders have been doing
This page follows insider dealings at Neurocrine Biosciences Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in San Diego, United States. The group dates from 1992. Between 18 October 2025 and 18 October 2026, 22 insiders published 106 filings.
No insider bought on the market over the period, while 8 insiders filed 21 sales totalling €44.8M. The amount is not disclosed for 3 filings. The largest single trade was a sale of €32.6M by Gorman Kevin Charles, published on 21 May 2026, equal to 0.20% of the market capitalisation.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 106 filings here. The full history, which starts in 2016, counts no purchases against 140 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 2.86 bn USD and net income at 478.6 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
360
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€73M
140 ops. · all time
Who traded when
BuySaleJulie Cooke5 sales
Darin Lippoldt4 sales
Ingrid Delaet4 sales
David W. Boyer2 sales
Eric Benevich2 sales
Kevin Charles Gorman2 sales
+3 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Neurocrine Biosciences Inc Strong Buy (bullish), based on 29 analysts. Average price target: US$206.81.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 4,890 of 24,148 companies
66.7
score / 100
Value48
Quality86
FCF yld5.4%
Earn yld3.5%
EV/EBITDA21.3x
ROE22%
Gross mgn98%
Net mgn17%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$135.91
Analyst consensus
29 analystsStrong buy
US$150.00Target US$206.81(+52%)US$253.00
Income statement
RevenueUS$2.9B
Gross profitUS$2.8B98% margin
EBITDAUS$666.6M23% margin
Net incomeUS$478.6M20.9% margin
Valuation
PER (trailing)19.8x
PER (forward)11.4x
P/Book3.7x
Beta0.40
Balance sheet & cash
Market capUS$13.8B
Total debtUS$415.3M
Free Cash FlowUS$748.7M
Debt / Equity12%
Profitability & ownership
ROE22.1%
ROA11.7%
% insiders1.1%
% institutions102.9%
Last declaration on 15 September 2026
Declarations360 total
4,483 shares0Common StockSEC:0001965808-26-000015:0
4,483 shares0Common StockSEC:0001504783-26-000019:0
7,839 shares@ US$156.220.0085% mcap1.9% of flowCommon StockSEC:0001201096-26-000018:1
2,419 shares@ US$156.220.0026% mcap3.7% of flowCommon StockSEC:0001504783-26-000019:1
5,020 shares0Common StockSEC:0001724097-26-000010:0
2,709 shares@ US$156.220.0029% mcap7.0% of flowCommon StockSEC:0001724097-26-000010:1
2,311 shares@ US$157.19810.0025% mcap6.0% of flowCommon StockSEC:0001724097-26-000010:2
6,275 shares0Common StockSEC:0001643653-26-000018:0
3,386 shares@ US$156.220.0037% mcap4.9% of flowCommon StockSEC:0001643653-26-000018:1
3,587 shares0Common StockSEC:0001909817-26-000010:0
1,936 shares@ US$156.220.0021% mcap10.0% of flowCommon StockSEC:0001909817-26-000010:1
826 shares@ US$157.44620.0009% mcap4.3% of flowCommon StockSEC:0001909817-26-000010:2
3,587 shares0Common StockSEC:0001776977-26-000013:0
2,419 shares@ US$156.220.0026% mcap4.6% of flowCommon StockSEC:0001965808-26-000015:1
14,343 shares0Common StockSEC:0001201096-26-000018:0
3,914 shares0Common StockSEC:0001818524-26-000006:0
2,112 shares@ US$156.220.0023% mcap100.0% of flowCommon StockSEC:0001818524-26-000006:1
3,587 shares0Common StockSEC:0001894425-26-000020:0
1,936 shares@ US$156.220.0021% mcap3.5% of flowCommon StockSEC:0001894425-26-000020:1
1,936 shares@ US$156.220.0021% mcap2.1% of flowCommon StockSEC:0001776977-26-000013:1
2,311 shares@ US$156.220.0025% mcap100.0% of flowCommonSEC144:0001950047-26-009441
25 of 360 declarations
About Neurocrine Biosciences Inc
Neurocrine Biosciences Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States, with corporate headquarters in San Diego, California. The company was founded in 1992 by Wylie Vale, Ph.D. of the Salk Institute and Lawrence Steinman, Ph.D. of Stanford University. From the outset, Neurocrine has been built around neuroscience-driven drug discovery, with a mission focused on underserved patient populations and difficult-to-treat diseases.
Neurocrine’s business model combines research, clinical development, and commercialization of specialty medicines. Its core therapeutic focus spans neurological, psychiatric, endocrine, and immunological disorders. The company already has a meaningful commercial franchise and a deeper clinical pipeline, which gives it a hybrid profile: part established product company, part development-stage innovator. Among its approved medicines are INGREZZA, used in certain movement disorders linked to dopamine regulation, and CRENESSITY, approved for classic congenital adrenal hyperplasia. Neurocrine also participates in strategic collaborations that can generate royalties or expand the reach of its scientific platform.
Read moreShow less
From a competitive standpoint, Neurocrine is best viewed as a focused specialist rather than a broad-based large-cap pharma group. Its strengths lie in deep domain expertise in neuroscience, disciplined clinical execution, and an ability to convert scientific insights into approved therapies. That focus can be a source of differentiation and pricing power, but it also means the company depends heavily on a limited number of commercial assets and the success of a relatively concentrated pipeline. For investors, this creates a mix of upside optionality and product-concentration risk.
Geographically, the company remains primarily centered on the United States, which is both its main operating base and its key commercial market. Its R&D and clinical programs, however, may extend beyond domestic boundaries through trials, regulatory work, and collaboration structures. Neurocrine continues to emphasize rare and under-addressed diseases, especially in areas where it believes it can meaningfully shift standards of care.
Recent highlights underscore that strategic direction. In 2025 and 2026, Neurocrine continued to release quarterly financial results, publish its 2025 annual report, and present new clinical data, including phase 2 findings for osavampator in major depressive disorder and CAH registry analyses related to classic congenital adrenal hyperplasia. Overall, the company’s recent news flow supports a clear investment narrative: defend and grow its commercial base while advancing a pipeline that could broaden long-term value creation on the NASDAQ in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
